Armin Reininger
Corporate Officer/Principal at SWEDISH ORPHAN BIOVITRUM AB
Net worth: 418 120 $ as of 2024-03-30
Profile
Armin Reininger is Head-Global Medical & Scientific Affairs at Swedish Orphan Biovitrum AB. In the past he held the position of Head-Global Medical Affairs Hematology at Baxalta, Inc. and Professor at Ludwig-Maximilians-Universität München. Dr. Reininger received a doctorate from Ludwig-Maximilians-Universität München.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-06-08 | 16,732 ( 0.00% ) | 418 120 $ | 2024-03-30 |
Armin Reininger active positions
| Companies | Position | Start |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 2017-01-05 |
Former positions of Armin Reininger
| Companies | Position | End |
|---|---|---|
| BAXALTA INC | Chief Tech/Sci/R&D Officer | - |
| Ludwig-Maximilians-Universität München | Corporate Officer/Principal | - |
Training of Armin Reininger
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Private companies | 1 |
|---|---|
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
- Stock Market
- Insiders
- Armin Reininger
